B+
Bull case
25%
Probability
Target price
$120.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
ABT
Abbott LaboratoriesDNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
Device growth, cancer diagnostics and a successful Nutrition separation could support a higher-growth remaining company. Abbott's reported Q3 revenue modestly exceeded the $12.99 billion estimate cited by Investing.com, but that is not a broad earnings beat.
Posture
Defensive
Lead driver
Value
What changed
6 setup hits (3d) with net bullish as of 2026-10-25.
What can break
Adjusted EPS excludes specified items; Q3 GAAP EPS was $0.53 versus adjusted EPS of $1.42. [#SEC-8K-2026-10-21]
Momentum
39
Value
54
Sentiment
47
Setup hits (3d)
6 · Net Bullish
AI TargetsBase $103.00 · Bull $120.00 · Bear $84.00Analysis 2026-10-22; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $119.76
Why
Momentum39 · Δ7d +11.2
Value54 · Δ7d +0.3
Sentiment47 · Δ7d -10.2
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 6 setup hits (3d) with net bullish as of 2026-10-25.
- • Value remains the lead driver in the composite, 7D delta +0.3.
Contradictions & invalidation
- • Adjusted EPS excludes specified items; Q3 GAAP EPS was $0.53 versus adjusted EPS of $1.42. [#SEC-8K-2026-10-21]
- • Exact Sciences integration and cancer-screening launches may not convert adoption into expected margins or cash flow. [#REL-aee43093-e6cc-4c1f-82f0-a1343d236c07]
- • The comparable-sales guide fell from 6.5%–7.5% to about 6%, and adjusted EPS of $1.42 was roughly in line with pre-print expectations; Zacks used a $1.43 consensus and called it a one-cent miss.
Catalyst clock
2026-10-22
Q3 print and reduced sales-growth outlook
Lead driver: Value · See fundamentals
Momentum
39
8% active weight
Current posture
7d trendImproving
Δ7d
+11.2
Δ21d
+19.2
Value
54
47% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
-0.7
Sentiment
47
45% active weight
Current posture
7d trendSoftening
Δ7d
-10.2
Δ21d
-28.3
Why this grade
Composite grade D. Momentum 38.7 / Value 54.4 / Sentiment 47.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-22. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$103.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$84.00
Analysis reference price unavailable
Analysis 2026-10-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$179.44B
Beta
0.75
Shares Out
1.73B
P/E (TTM)
15.8
P/S (TTM)
5.02
P/FCF (TTM)
76.53
Rev YoY
+13.0%
EPS YoY
-48.2%
Gross Margin
+52.8%
Op Margin
+16.4%
Net Debt
$5.2B
Current Ratio
1.38
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data